In the OCTANE real-world analysis presented at EASD 2026, adults who switched from injectable semaglutide or tirzepatide to once-daily oral semaglutide lost an average of 4.1% of body weight after 3 months.
News|Articles|March 2, 2026
BioPharm International Sponsored eBooks
- BioPharm International Sponsored eBooks-2-26-26
Smarter Decisions, Stronger Medicines: The Role of Advanced Analytics
Author(s)Thermo Fisher Scientific
Pharmaceutical and biopharmaceutical companies are navigating tightening regulations, rising R&D costs, and intensifying competition, prompting a comprehensive reassessment of their production systems. By leveraging advanced analytics and modern technologies across the product lifecycle—from discovery through approval—organizations can enhance efficiency, strengthen quality and consistency, and enable more agile, data-driven manufacturing. This eBook examines how advanced analytical tools complement traditional methods to support faster, more confident decision-making within increasingly complex development and manufacturing environments.
Related to this article
Denosumab-adet now covers all 3 Xgeva indications, widening lower-cost treatment access for cancer patients with bone complications.
More than half of patients achieved clear or almost clear hands and feet with lebrikizumab by week 16, and 77% reported satisfaction with clearance.
Sponsored
Meeta Gulyani, Ecolab Life Sciences, shares where biomanufacturing is headed next and why the relationship between drug developers and their suppliers is changing along with it.
Novo Nordisk licenses a once-weekly oral GLP-1/GIP candidate, uniQure reports 48-month Huntington’s disease data, and AstraZeneca invests $2 billion in Summit Therapeutics.
Novo gains global rights, excluding Greater China, to HRS-1596, a phase 1-ready GLP-1/GIP dual receptor agonist that Hengrui says has potential for once-weekly oral dosing in obesity and type 2 diabetes.
NouvSight001 isn't limited to the RPE65-mutation subset current gene therapy treats, potentially reaching more of the 1.5 million with RP worldwide.
Updated 36-month data in 15 high-dose patients showed 80% slowing on cUHDRS, while the 48-month cUHDRS result did not reach statistical significance. uniQure attributes the gap to attrition in the external control, and the FDA is reviewing a BLA based on the 36-month data.